Guardant Health
@guardanthealth.bsky.social
š¤ 109
š„ 70
š 90
Conquering Cancer With Dataš©ø
Weāre honored to share that the FDA has approved Guardant360Ā® CDx as a companion diagnostic for BRAF V600Eāmutant metastatic
#ColorectalCancer
, helping identify patients who may benefit from BRAFTOVIĀ® (encorafenib)ābased treatment. Details:
bit.ly/49ODNh8
9 days ago
0
0
0
Together with Merck, weāre advancing the development and global commercialization of new cancer therapies through a multi-year strategic collaboration leveraging our Guardant Infinity⢠Smart Platform. More details:
bit.ly/4k0Od23
10 days ago
0
0
0
Weāre looking forward to joining the healthcare and investment community at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, where our management team will present and participate in a live Q&A on Monday, January 12 at 3:45pm PT. More details:
bit.ly/3N7tsWf
20 days ago
0
1
0
Our Shield⢠blood test for
#ColorectalCancer
screening is now covered by
@tricare.bsky.social
, making it available to active-duty U.S. service members and family members ages 45 and older. More details:
bit.ly/3Nzjwoo
23 days ago
0
1
0
Onward to 2026, a new year to remain driven by purpose, grounded in science, and focused on what matters most: patients. Hereās to moving forward with clarity, momentum, and continued innovation.
26 days ago
0
1
0
For the fourth year in a row, weāve been named to
@computerworld.com
ās
#BestPlacesIT
list, ranking 18 among midsize organizations for 2026. Truly grateful to our global technology teams for the culture that drives our mission forward. Details:
bit.ly/4oOLbyI
about 2 months ago
0
1
0
Today we announced a collaboration with Trial Library that unites our large-scale genomic data & their AI-powered matching & navigation platform to help more patients, including those in underserved communities, reach the right precision oncology clinical trials. Details:
bit.ly/4rQFanR
about 2 months ago
0
1
0
Introducing FPG 360, one of Italyās first in-house liquid biopsy testing services at the Policlinico Gemelli in Rome. Powered by our Guardant360Ā® CDx technology, this new service expands access to precision oncology diagnostics & supports both routine care &
#ClinicalResearch
. Info:
bit.ly/44SFOax
about 2 months ago
0
1
0
We look forward to sharing new data at
#SABCS25
, where we will present 14 abstracts demonstrating the power of multiomic liquid biopsy testing in predicting outcomes & tailoring treatment for patients with early and metastatic
#BreastCancer
. Details:
bit.ly/49TyQpc
loading . . .
about 2 months ago
0
0
0
Shield⢠is poised to change how the U.S. screens for
#ColorectalCancer
but outdated guidelines are holding back access. Our Co-CEO AmirAli Talasaz outlines why millions remain unscreened despite the availability of the first FDA-approved blood test for primary CRC screening. Read:
bit.ly/4rFXFvl
about 2 months ago
0
2
0
As MRD testing becomes integral to clinical development, understanding tissue-informed vs. tissue-free approaches is key. Join us on Monday, November 24 at 2PM PT to explore the latest in MRD for
#BreastCancer
. Register:
bit.ly/48kthPa
2 months ago
0
1
0
reposted by
Guardant Health
National Council on Aging
3 months ago
Colorectal cancer is often silent in its early stages. We can change that by spreading the word about the importance of early detection! š£
#NoShaveNovember
is the perfect time to encourage regular screening among the older adults you serve. Get the facts and help
#FightCRC
. ā¬ļø
loading . . .
Protect Your Colon Health: Know the Signs & Screening Options
Colorectal cancer is the 2nd leading cause of cancer deaths in the U.S., but early detection can save lives. Learn the warning signs and which screening options could be right for you.
https://www.ncoa.org/article/colorectal-cancer-stages-symptoms-and-easier-screening-options/?utm_source=Bluesky&utm_medium=Social&utm_campaign=OrgSocial
0
3
1
Weāre excited to announce the launch of the Single Namespace Working Group, a 34-member consortium uniting leading technology, healthcare, & research organizations to establish the first open standard for exabyte-scale data interoperability. Details:
bit.ly/3JZUU6X
loading . . .
3 months ago
0
1
0
The next evolution of Guardant RevealĀ® is here. Details:
bit.ly/3Xn7AaY
loading . . .
3 months ago
0
1
0
A
#NewStudy
published in The Journal of Liquid Biopsy validates the effectiveness of our Guardant RevealĀ® blood test in monitoring chemotherapy response across advanced cancers. Details:
bit.ly/4oRkUjB
loading . . .
3 months ago
0
0
0
Real-world evidence continues to build for Shieldā¢: A new study published in Current Medical Research and Opinion found that Shield demonstrates 95% patient adherence for
#ColorectalCancer
screening among 20,000 patients. Details:
bit.ly/3LhRgFY
3 months ago
0
1
0
Tomorrow, our Co-CEO AmirAli Talasaz joins global health leaders at
#MIHealthSummit
for a panel exploring how we can make health care access more personal, preventive, & proactive. Watch live tomorrow:
bit.ly/43UBqHv
3 months ago
0
0
0
We have reported our third quarter 2025 financial results, highlighted by 39% year-over-year revenue growth. Our continued momentum has led us to raise our full-year 2025 revenue guidance to $965ā$970 million, representing 31% year-over-year growth. Details:
bit.ly/4nBoZaJ
loading . . .
3 months ago
0
0
0
Weāre proud to announce a strategic partnership with Zephyr AI to deliver novel, scalable, & actionable insights that support biopharma innovation, reflecting our shared commitment to leveraging AI and multimodal data to advance
#CancerResearch
and improve
#PatientCare
.
loading . . .
Guardant Health and Zephyr AI Announce Partnership to Unlock Drug Response Predictions and Biomarker Insights
Strategic partnership will link DNA data with rich clinical data to identify novel biomarkers for targeted cancer therapies The two companies will utilize AI and multimodal molecular data to unlock ne...
https://bit.ly/4qwqR7d
3 months ago
0
0
0
We're sharing data at
#ACG2025
, highlighting the critical role of blood-based testing in improving
#CancerScreening
adherence. Data presentation details:
bit.ly/4odIp6K
3 months ago
0
0
0
Weāre excited to be at
#JADPROLive
in National Harbor, Maryland! Stop by Booth #510 to meet our medical affairs team and explore the vital role oncology advanced practitioners play in advancing precision cancer care through molecular testing.
3 months ago
0
0
0
Innovations in cancer diagnostics are transforming the landscape of care. The latest
@milkeninstitute.org
Institute report explores how liquid biopsies ā noninvasive, blood-based tests ā can revolutionize
#CancerDetection
and treatment. Read more:
bit.ly/4opJhVy
loading . . .
A Pivotal Role: Liquid Biopsies in the Future of Cancer Care | Milken Institute
Cancer care is entering a new era. Despite decades of investment and remarkable breakthroughs, the disease continues to affect millions of people each yearāan
https://bit.ly/4opJhVy
3 months ago
0
2
2
Weāre excited to share our latest data this week at
#ESMO25
! šVisit us at Booth 3021 to learn more. Additional details:
bit.ly/4nVIQCu
loading . . .
4 months ago
0
1
0
Weāre proud to share that the FDA has approved our Guardant360Ā® CDx test as a companion diagnostic for
@elilillyandcompany.bsky.social
's Inluriyo⢠(imlunestrant) for ESR1-mutated advanced
#BreastCancer
. More details:
investors.guardanthealth.com/press-releas...
4 months ago
0
1
0
Weāre proud to be a partner of the World Clinical Biomarkers & Companion Diagnostics Summit next week. Join our plenary session with Jean-Francois Martini to learn how our flexible solutions combined with multimodal real-world data and can streamline your
#ClinicalDevelopment
program for success.
5 months ago
0
1
0
We are proud to welcome Alex M. Azar II to our board of directors. Secretary Azar brings a unique perspective on the intersection of policy, innovation, and patient access that will help us advance our mission to conquer cancer with data. Details:
bit.ly/4gmjZom
5 months ago
0
1
0
Today weāre excited to announce a new partnership with PathGroup to expand access to our Shieldā¢
#BloodTest
for early cancer detection. Through PathGroupās extensive network, Shield will soon be available in more than 250 hospitals and 15,000 physicians across 25 states. Details:
bit.ly/4peK392
5 months ago
0
1
0
On Tuesday, our Co-CEO Helmy Eltoukhy will join
@wired.com
at
#WIREDHealth
for a featured conversation: āWinning the War on Cancer." Helmy will explore how liquid biopsies are driving earlier detection, faster treatment decisions, & a more personalized patient experience. Info:
lnkd.in/e3KvKNsa
5 months ago
0
0
0
This past weekend, we teamed up with the Dolphins Cancer Challenge before the Dolphins took on the Jaguars to connect with fans and share more about Shieldā¢, the blood test that screens for
#ColonCancer
the more pleasant way. A big
#ThankYou
to all the fans who joined the conversation with us!
5 months ago
0
0
0
Today we announced that the 1st patient has been enrolled in the the National Cancer Institute's Vanguard Study, evaluating our Shield⢠MCD test. The 4-year study will assess the feasibility of using blood-based tests to detect multiple cancers in individuals w/o symptoms. Details:
bit.ly/40jXcms
7 months ago
0
0
0
Join us for a live
#Webinar
on the power of epigenomic biomarkers to improve patient selection and better predict treatment response in oncology clinical trials. Register today:
bit.ly/44kpIa3
š Date: July 24 š Time: 9:00am PT
7 months ago
0
0
0
Last week, our co-CEO AmirAli Talasaz took the stage at
#AspenIdeasHealth
on the New Frontiers in Cancer panel, a timely discussion on how breakthroughs in blood-based screening, precision medicine, & AI are reshaping the future of care. Watch the session:
bit.ly/4kt5yQ0
Photo credit: Leigh Vogel
7 months ago
0
0
0
At
#AspenIdeasHealth
, our co-CEO AmirAli Talasaz sat down with
@drjohntorres.bsky.social
to discuss a critical gap in cancer care: screening technologies are advancing, but access isnāt keeping pace.
loading . . .
7 months ago
0
0
0
Exciting news! Our Shield⢠blood test has been recognized on
@fastcompany.com
's 2025 World Changing Ideas list! We're thrilled to be part of this amazing collection of ideas driving meaningful change in the world. Check out the full list here:
fastcompany.com/world-changi...
#FCWorldChangingIdeas
8 months ago
0
2
1
Today, weāre proud to share that ESMO Open has published results from the LIBERATE study, highlighting Guardant Revealās performance in detecting minimal residual disease in early-stage
#BreastCancer
. Details:
bit.ly/43yOanC
8 months ago
0
0
0
We're honored to announce that our Shield multi-cancer detection (MCD) test has been granted Breakthrough Device designation from the
@fda.gov
. More details:
investors.guardanthealth.com/press-releas...
8 months ago
0
0
0
Featured in
@nytimes.com
: Our Guardant360Ā® CDx test is helping revolutionize
#BreastCancer
treatment by detecting drug resistance before it shows up on scansāenabling timely treatment changes and improving patient outcomes.
loading . . .
Drug-Defying Breast Cancers Spotted Early in Blood Test Study
https://www.nytimes.com/2025/06/01/health/breast-cancer-blood-test-astrazeneca.html?smid=nytcore-ios-share&referringSource=articleShare
8 months ago
0
0
0
Weāre proud to share that the National Comprehensive Cancer Network has included our Shield⢠blood test in its updated
#ColorectalCancer
screening guidelines. Marking a pivotal step forward in expanding
#PatientAccess
to an innovative, blood-based screening option. Details:
bit.ly/3SxrayX
8 months ago
0
0
0
Today we announced results from the Phase III SERENA-6 trial, demonstrating the clinical value of our Guardant360Ā® CDx test in detecting & treating emerging resistance in advanced
#BreastCancer
ahead of radiological progression. Details:
bit.ly/4mJ3kxU
8 months ago
0
1
0
The future of precision oncology is here. Join us at
#ASCO25
, booth #25077, to discover the pivotal role of liquid biopsy in transforming cancer care and improving patient outcomes.
8 months ago
0
0
0
At
#ASCO25
yesterday, we shared results from the largest study to date evaluating ctDNA in
#ColonCancer
, highlighting the power of our Guardant Reveal⢠test to inform critical treatment decisions. More details:
bit.ly/4mFFHq1
8 months ago
0
1
0
Join us at
#ASCO25
for an exclusive event showcasing how our Guardant Infinity⢠platform is propelling patient-centered care into the future. Discover how redefining precision oncology through innovation & advocacy. š Monday, June 2 š 8 AMā5 PM š Marriott Marquis Chicago | Astronomy Room
8 months ago
0
0
0
Weāre excited to introduce nearly a dozen new applications for our Guardant360Ā® Liquid test, further enhancing its ability to identify biomarkers and subtype cancers from a blood sample. More details:
bit.ly/4dwo7AE
8 months ago
0
1
0
Weāre looking forward next week's 2025 ASCO Annual Meeting, where weāll share data from 19+ studies showcasing the critical role of our liquid biopsy tests in cancer screening, therapy selection, & recurrence monitoring. Stop by booth #25077 at
#ASCO25
to learn more. Details:
bit.ly/4myVcjK
loading . . .
8 months ago
0
0
0
Today we announced the addition of an extensive suite of immunohistochemistry testing to our portfolio of tumor molecular profiling tests, further supporting oncologists in identifying tumor subtypes and matching cancer patients to the most effective targeted therapies. Details:
bit.ly/3SM8xr6
9 months ago
0
1
0
Introducing the Guardant Hereditary Cancer test ā our germline test designed to identify inherited genetic variants associated with cancer risk across more than 12 tumor types, helping cancer care teams provide optimal patient care. Learn more:
bit.ly/4dtyQMv
9 months ago
0
1
0
ICYMI: Our Chairman & co-CEO Helmy Eltoukhy joined
@bloomberg.com
at
#MIGlobal
to share how Guardant is using blood-based testing, DNA sequencing, and AI to detect cancer earlier, speed up diagnosis, and lower healthcare costs.
www.youtube.com/watch?v=vrZF...
loading . . .
Chairman and co-CEO Helmy Eltoukhy Speaks with Bloomberg | Milken Institute Global Conference 2025
YouTube video by Guardant Health
https://www.youtube.com/watch?v=vrZFzMnEQbg
9 months ago
0
0
0
Weāre proud to share that weāre
#GPTWCertified
in the U.S. for the 3rd straight year! This recognition is a testament to the culture our team fosters every dayāinclusive, collaborative, and deeply rooted in our mission to conquer cancer with data. š:
bit.ly/457yusw
9 months ago
0
0
0
Today at
#AACR25
, we shared new data showing that our Shield⢠multi-cancer detection test demonstrated strong performance across ten cancer types. The study was a critical step in evaluating this innovative technology to detect multiple cancers through a simple blood draw. Details:
bit.ly/3YOLBuD
9 months ago
0
13
2
Introducing Guardant360 Tissue: a new standard in tissue cancer profiling. Leveraging multiomics and powered by Guardant Infinityā¢, Guardant360 Tissue delivers a more complete view of cancer yet requires 40% less tissue, so more patients can be tested. More details:
bit.ly/4lPc4Cj
9 months ago
0
0
0
Load more
feeds!
log in